New York Genome Center Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
OPERATE A STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O.
- Income
- $82.3 million
- Spending
- $84.3 million
- Spent on programs
- 81%
- Reserves
- -4.1 months of spending
- Largest source of income
- donations and private grants, 65%
- Employees
- 284
- Volunteers
- 27
- Highest pay
- $675,040, scientific director & ceo
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Weak: 33 out of 100. Higher than 10% of charities in its peer group (health care, $10m to $100m).
Reserves
0 of 35Spendable reserves are negative: it owes or has committed more than it holds.
Debt
5 of 20It owes 74% of what it owns.
Living within its means
8 of 15Spending exceeded income by 2% of income.
Income trend
5 of 15Income fell 11% on the year before.
Spending floor
15 of 1581% of spending went to programs and raising each dollar of donations cost 2 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 52% of charities in its peer group (health care, $10m to $100m).
Independent board
25 of 2523 of 24 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (2)
- $60.5 million spent. GENOME SEQUENCING: THE NEW YORK GENOME CENTER (NYGC) HAS ONE OF NEW YORK'S LARGEST AND MOST ADVANCED WHOLE GENOME SEQUENCING PROGRAMS, HAVING SEQUENCED OVER 106,885 WHOLE GENOME SAMPLES TO DATE. NYGC'S TWO STATE-OF-THE-ART ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS ARE EACH CAPABLE OF SEQUENCING 20,000 HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). SEE SCHEDULE O. NYGC IS COMMITTED TO ADVANCING GENOMIC SCIENCE TO DRIVE NOVEL BIOMEDICAL DISCOVERIES AND TRANSFORM PATIENT CARE THROUGH PRECISION MEDICINE. RESEARCH AND FACULTY NYGC MAINTAINS A STRONG COMMITMENT TO RECRUITING OUTSTANDING FACULTY WITH BROAD EXPERTISE IN DISEASE GENOMICS, COMPUTATIONAL AND MACHINE LEARNING APPROACHES, ENGINEERING, AND GENOMIC TECHNOLOGIES. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. EACH FACULTY MEMBER HAS BUILT A ROBUST RESEARCH PROGRAM AND HOLDS A JOINT TENURE-TRACK APPOINTMENT AT ONE OF OUR PARTNER INSTITUTIONS. NYGC ALSO HAS A DISTINGUISHED GROUP OF SENIOR ASSOCIATE FACULTY, AFFILIATE MEMBERS, AND A SCIENTIFIC ADVISORY BOARD (SAB) COMPRISED OF WORLD-LEADERS IN GENOMICS AND WHO BRING INVALUABLE SCIENTIFIC LEADERSHIP AND MENTORSHIP TO THE CENTER. OUR SENIOR LEADERSHIP TEAM, TOGETHER WITH THE EXTENSIVE EXPERIENCE AND GUIDANCE OF OUR SENIOR FACULTY AND SCIENTIFIC ADVISORY BOARD, EMPOWERS THE NEXT GENERATION OF GENOMIC RESEARCHERS TO PURSUE GROUNDBREAKING DISCOVERIES IN BIOMEDICAL RESEARCH, DRIVING ADVANCEMENTS THAT CAN TRANSFORM HEALTHCARE AND IMPROVE PATIENT OUTCOMES. IN 2024, NYGC SCIENTISTS PUBLISHED 78 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS, ESTABLISHING NEW INSIGHTS INTO THE CAUSES AND MECHANISMS OF DISEASE, INNOVATIVE NEW GENOMIC TECHNOLOGIES, AND NOVEL COMPUTATIONAL APPROACHES SHARED WIDELY WITH THE SCIENTIFIC COMMUNITY TO HELP ADVANCE PRECISION MEDICINE. TWO OF NYGC'S CORE FACULTY MEMBERS, RAHUL SATIJA, PHD, AND NEVILLE SANJANA, PHD, WERE ONCE AGAIN NAMED AMONG THE WORLD'S MOST CITED RESEARCHERS ON CLARIVATE ANALYTICS' 2024 HIGHLY CITED RESEARCHERS LIST FOR THE SIXTH CONSECUTIVE YEAR, A TESTAMENT TO THEIR IMPACTFUL CONTRIBUTIONS AND INFLUENCE IN THEIR RESPECTIVE FIELDS OF STUDY. THIS ANNUAL LIST GATHERS THOSE IN THE FIELD WHO DEMONSTRATED SIGNIFICANT AND BROAD INFLUENCE REFLECTED IN THEIR PUBLICATIONS OF MULTIPLE HIGHLY CITED PAPERS OVER THE LAST DECADE. THE HIGHLY CITED PAPERS RANK IN THE TOP 1% BY CITATION FOR A FIELD OR FIELDS AND PUBLICATION YEAR IN THE WEB OF SCIENCE. IN 2024, NYGC EXPANDED ITS COMMITMENT TO SCIENTIFIC TRAINING WITH THE LAUNCH OF ITS EARLY CAREER DEVELOPMENT PROGRAM FOR POST-BACCALAUREATES. THIS PROGRAM WELCOMED ITS FIRST COHORT OF ASPIRING RESEARCHERS WITH THE OPPORTUNITY TO GAIN HANDS-ON RESEARCH EXPERIENCE IN GENOMICS, COMPUTATIONAL BIOLOGY, TECHNOLOGY INNOVATION, AND CLINICAL GENETIC TESTING. NYGC HAS CONTINUED TO MAKE SIGNIFICANT PROGRESS IN ITS CORE RESEARCH AREAS. NOTEWORTHY EXAMPLES OF THIS PROGRESS INCLUDE: CANCER: NYGC'S SIGNATURE POLYETHNIC-1000 (P-1000) IS A MULTI-INSTITUTIONAL COLLABORATIVE EFFORT LED BY DRS. HAROLD VARMUS AND CHARLES SAWYERS, NYGC'S CANCER GROUP, AND LEADERS FROM ACROSS NEW YORK CITY'S CANCER RESEARCH COMMUNITY, LEVERAGING THE CITY'S EXTRAORDINARY DIVERSITY TO ADVANCE CANCER GENOMICS AND ITS APPLICATION IN CLINICAL CARE. DESIGNED TO DEMOCRATIZE CANCER GENOMICS THROUGH WHOLE-GENOME SEQUENCING, BIOINFORMATIC ANALYSIS, CLINICAL RESEARCH, AND COMMUNITY OUTREACH, P-1000 HAS CREATED A POWERFUL PLATFORM FOR UNDERSTANDING HOW DIFFERENT GENETIC BACKGROUNDS INFLUENCE CANCER. THIS WIDELY RECOGNIZED FRAMEWORK LAID THE FOUNDATION FOR TEAM SAMBAI, RECIPIENT OF THE PRESTIGIOUS CANCER GRAND CHALLENGE (CGC) AWARD. LED BY DR. MELISSA DAVIS, NYGC ASSOCIATE FACULTY MEMBER; DIRECTOR, INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE, MOREHOUSE SCHOOL OF MEDICINE; SCIENTIFIC DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF BREAST CANCER SUBTYPES; DIRECTOR OF HEALTH EQUITY, ENGLANDER INSTITUTE OF PRECISION MEDICINE; AND ASSOCIATE PROFESSOR OF CELL AND DEVELOPMENTAL BIOLOGY, WEILL CORNELL MEDICINE, TEAM SAMBAI (SOCIETAL, ANCESTRY, MOLECULAR, AND BIOLOGICAL ANALYSES OF INEQUALITIES) UNITES EXPERTS IN CANCER GENOMICS, IMMUNOLOGY, EPIDEMIOLOGY, EXPOSOMICS, AND PATIENT ADVOCACY. SELECTED AS ONE OF ONLY FIVE INTERNATIONAL RESEARCH TEAMS, AND THE SOLE GROUP CHOSEN FROM A HIGHLY COMPETITIVE GLOBAL POOL FOCUSED ON CANCER INEQUITIES - ONE OF THE NINE CGC-IDENTIFIED TOUGHEST CHALLENGES IN CANCER IN 2024 - TEAM SAMBAI WILL RECEIVE UP TO $25 MILLION IN FUNDING TO CARRY THIS VITAL WORK FORWARD. NEURODEGENERATIVE DISEASE: THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), AT NYGC, LED BY NYGC CORE FACULTY MEMBER, HEMALI PHATNANI, PHD, HAS ESTABLISHED A GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONSORTIUM, CONSISTING OF 46 MEMBER INSTITUTIONS WORLDWIDE. THE CGND HAS ALSO CONTRIBUTED TO ALS RESEARCH WITH THE DEVELOPMENT OF GENOMIC TECHNOLOGIES FOR THE STUDY OF RNA, SINGLE CELL AND SPATIALLY-RESOLVED TRANSCRIPTOMICS. NYGC LEVERAGES THE SUCCESS OF THE CGND'S FOCUS ON ALS RESEARCH TO EXTEND THIS WORK ACROSS A WIDER RANGE OF NEURODEGENERATIVE DISEASES THAT SHARE COMMON PATHWAYS WITH ALS; SUCH DISEASES INCLUDE VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA (FTD), PARKINSON'S DISEASE, AND HUNTINGTON'S DISEASE. DR. HEMALI PHATNANI'S LAB AT NYGC, IN COLLABORATION WITH THE ALS CONSORTIUM, MADE SIGNIFICANT STRIDES
- $7.7 million spent. CLINICAL SEQUENCING: NYGC'S CLEP/CLIA CERTIFIED CLINICAL LABORATORY IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, MATERNAL CELL CONTAMINATION TESTING, AND ANEUPLOIDY SCREENING. NYGC IS COMMITTED TO ADVANCING GENOMIC SCIENCE TO DRIVE NOVEL BIOMEDICAL DISCOVERIES AND TRANSFORM PATIENT CARE THROUGH PRECISION MEDICINE. RESEARCH AND FACULTY NYGC MAINTAINS A STRONG COMMITMENT TO RECRUITING OUTSTANDING FACULTY WITH BROAD EXPERTISE IN DISEASE GENOMICS, COMPUTATIONAL AND MACHINE LEARNING APPROACHES, ENGINEERING, AND GENOMIC TECHNOLOGIES. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. EACH FACULTY MEMBER HAS BUILT A ROBUST RESEARCH PROGRAM AND HOLDS A JOINT TENURE-TRACK APPOINTMENT AT ONE OF OUR PARTNER INSTITUTIONS. NYGC ALSO HAS A DISTINGUISHED GROUP OF SENIOR ASSOCIATE FACULTY, AFFILIATE MEMBERS, AND A SCIENTIFIC ADVISORY BOARD (SAB) COMPRISED OF WORLD-LEADERS IN GENOMICS AND WHO BRING INVALUABLE SCIENTIFIC LEADERSHIP AND MENTORSHIP TO THE CENTER. OUR SENIOR LEADERSHIP TEAM, TOGETHER WITH THE EXTENSIVE EXPERIENCE AND GUIDANCE OF OUR SENIOR FACULTY AND SCIENTIFIC ADVISORY BOARD, EMPOWERS THE NEXT GENERATION OF GENOMIC RESEARCHERS TO PURSUE GROUNDBREAKING DISCOVERIES IN BIOMEDICAL RESEARCH, DRIVING ADVANCEMENTS THAT CAN TRANSFORM HEALTHCARE AND IMPROVE PATIENT OUTCOMES. IN 2024, NYGC SCIENTISTS PUBLISHED 78 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS, ESTABLISHING NEW INSIGHTS INTO THE CAUSES AND MECHANISMS OF DISEASE, INNOVATIVE NEW GENOMIC TECHNOLOGIES, AND NOVEL COMPUTATIONAL APPROACHES SHARED WIDELY WITH THE SCIENTIFIC COMMUNITY TO HELP ADVANCE PRECISION MEDICINE. TWO OF NYGC'S CORE FACULTY MEMBERS, RAHUL SATIJA, PHD, AND NEVILLE SANJANA, PHD, WERE ONCE AGAIN NAMED AMONG THE WORLD'S MOST CITED RESEARCHERS ON CLARIVATE ANALYTICS' 2024 HIGHLY CITED RESEARCHERS LIST FOR THE SIXTH CONSECUTIVE YEAR, A TESTAMENT TO THEIR IMPACTFUL CONTRIBUTIONS AND INFLUENCE IN THEIR RESPECTIVE FIELDS OF STUDY. THIS ANNUAL LIST GATHERS THOSE IN THE FIELD WHO DEMONSTRATED SIGNIFICANT AND BROAD INFLUENCE REFLECTED IN THEIR PUBLICATIONS OF MULTIPLE HIGHLY CITED PAPERS OVER THE LAST DECADE. THE HIGHLY CITED PAPERS RANK IN THE TOP 1% BY CITATION FOR A FIELD OR FIELDS AND PUBLICATION YEAR IN THE WEB OF SCIENCE. IN 2024, NYGC EXPANDED ITS COMMITMENT TO SCIENTIFIC TRAINING WITH THE LAUNCH OF ITS EARLY CAREER DEVELOPMENT PROGRAM FOR POST-BACCALAUREATES. THIS PROGRAM WELCOMED ITS FIRST COHORT OF ASPIRING RESEARCHERS WITH THE OPPORTUNITY TO GAIN HANDS-ON RESEARCH EXPERIENCE IN GENOMICS, COMPUTATIONAL BIOLOGY, TECHNOLOGY INNOVATION, AND CLINICAL GENETIC TESTING. NYGC HAS CONTINUED TO MAKE SIGNIFICANT PROGRESS IN ITS CORE RESEARCH AREAS. NOTEWORTHY EXAMPLES OF THIS PROGRESS INCLUDE: CANCER: NYGC'S SIGNATURE POLYETHNIC-1000 (P-1000) IS A MULTI-INSTITUTIONAL COLLABORATIVE EFFORT LED BY DRS. HAROLD VARMUS AND CHARLES SAWYERS, NYGC'S CANCER GROUP, AND LEADERS FROM ACROSS NEW YORK CITY'S CANCER RESEARCH COMMUNITY, LEVERAGING THE CITY'S EXTRAORDINARY DIVERSITY TO ADVANCE CANCER GENOMICS AND ITS APPLICATION IN CLINICAL CARE. DESIGNED TO DEMOCRATIZE CANCER GENOMICS THROUGH WHOLE-GENOME SEQUENCING, BIOINFORMATIC ANALYSIS, CLINICAL RESEARCH, AND COMMUNITY OUTREACH, P-1000 HAS CREATED A POWERFUL PLATFORM FOR UNDERSTANDING HOW DIFFERENT GENETIC BACKGROUNDS INFLUENCE CANCER. THIS WIDELY RECOGNIZED FRAMEWORK LAID THE FOUNDATION FOR TEAM SAMBAI, RECIPIENT OF THE PRESTIGIOUS CANCER GRAND CHALLENGE (CGC) AWARD. LED BY DR. MELISSA DAVIS, NYGC ASSOCIATE FACULTY MEMBER; DIRECTOR, INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE, MOREHOUSE SCHOOL OF MEDICINE; SCIENTIFIC DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF BREAST CANCER SUBTYPES; DIRECTOR OF HEALTH EQUITY, ENGLANDER INSTITUTE OF PRECISION MEDICINE; AND ASSOCIATE PROFESSOR OF CELL AND DEVELOPMENTAL BIOLOGY, WEILL CORNELL MEDICINE, TEAM SAMBAI (SOCIETAL, ANCESTRY, MOLECULAR, AND BIOLOGICAL ANALYSES OF INEQUALITIES) UNITES EXPERTS IN CANCER GENOMICS, IMMUNOLOGY, EPIDEMIOLOGY, EXPOSOMICS, AND PATIENT ADVOCACY. SELECTED AS ONE OF ONLY FIVE INTERNATIONAL RESEARCH TEAMS, AND THE SOLE GROUP CHOSEN FROM A HIGHLY COMPETITIVE GLOBAL POOL FOCUSED ON CANCER INEQUITIES - ONE OF THE NINE CGC-IDENTIFIED TOUGHEST CHALLENGES IN CANCER IN 2024 - TEAM SAMBAI WILL RECEIVE UP TO $25 MILLION IN FUNDING TO CARRY THIS VITAL WORK FORWARD. NEURODEGENERATIVE DISEASE: THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), AT NYGC, LED BY NYGC CORE FACULTY MEMBER, HEMALI PHATNANI, PHD, HAS ESTABLISHED A GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONSORTIUM, CONSISTING OF 46 MEMBER INSTITUTIONS WORLDWIDE. THE CGND HAS ALSO CONTRIBUTED TO ALS RESEARCH WITH THE DEVELOPMENT OF GENOMIC TECHNOLOGIES FOR THE STUDY OF RNA, SINGLE CELL AND SPATIALLY-RESOLVED TRANSCRIPTOMICS. NYGC LEVERAGES THE SUCCESS OF THE CGND'S FOCUS ON ALS RESEARCH TO EXTEND THIS WORK ACROSS A WIDER RANGE OF NEURODEGENERATIVE DISEASES THAT SHARE COMMON PATHWAYS WITH ALS; SUCH DISEASES INCLUDE VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA (FTD), PARKINSON'S DISEASE, AND HUNTINGTON'S DISEASE. DR. HEMALI PHATNANI'S LAB AT NYGC, IN COLLABORATION WITH THE ALS CONSORTIUM, MADE SIGNIFICANT STRIDES IN ALS RESEARCH IN 2024 BY IDENTIFYING THREE DISTINCT MOLECULAR SUBTYPES OF THE DISEASE. THESE MOLECULAR SUBTYPES WERE FOUND TO CORRELATE WITH SPECIFIC PATTERNS OF GENE EXPRESSION, AND EACH HAD DISTINCT CLINICAL FEAT
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since January 2012.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.